TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis
Valle Palomo(Biomedical Research Networking Center on Neurodegenerative Diseases), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Vanesa Nozal(Centro de Investigaciones Biológicas Margarita Salas), Carlota Tosat‐Bitrián(Centro de Investigaciones Biológicas Margarita Salas), Ángeles Martín‐Requero(Centro de Investigación Biomédica en Red), Siranjeevi Nagaraj(Université Libre de Bruxelles)
Cited by 46
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293